| Balance Sheets | 2025-08-31 | |||
|---|---|---|---|---|
| Cash | 1,802,123 | |||
| Short-term investments | 143,267 | |||
| Marketable securities | 22,093 | |||
| Accounts receivable | 368,358 | |||
| Prepaid expenses and other current assets | 1,132,504 | |||
| Total current assets | 3,468,345 | |||
| Long-term receivables | 64,013 | |||
| Right of use assets | 106,816 | |||
| Intellectual property, net | 307,818 | |||
| Property & equipment, net | 228,129 | |||
| Total non-current assets | 706,776 | |||
| Total assets | 4,175,121 | |||
| Accounts payable and accrued liabilities | 1,463,046 | |||
| Deferred revenue | 0 | |||
| Lease liability, current | 30,417 | |||
| Total current liabilities | 1,493,463 | |||
| Lease liabilities - non-current | 78,903 | |||
| Total liabilities | 1,572,366 | |||
| Share capital authorized 220,000,000 common voting shares with a par value of 0.001 per share common shares issued and outstanding 19,559,179 and 15,810,205 at august 31, 2025 and august 31, 2024, respectively | 19,559 | |||
| Additional paid-in capital | 66,501,086 | |||
| Accumulated deficit | -63,460,613 | |||
| Accumulated other comprehensive loss | -70,335 | |||
| Equity attributable to shareholders of lexaria | 2,989,697 | |||
| Non-controlling interest | -386,942 | |||
| Total stockholders' equity | 2,602,755 | |||
| Total liabilities and stockholders' equity | 4,175,121 | |||
Lexaria Bioscience Corp. (LEXXW)
Lexaria Bioscience Corp. (LEXXW)